医学
克里唑蒂尼
ROS1型
内科学
肺癌
不利影响
肿瘤科
纳入和排除标准
癌症
腺癌
病理
替代医学
恶性胸腔积液
作者
Israr Khan,Atiya Sahar,Suhaiba Numra,Nilanjan Saha,Nidhi Agarwal,Rizwana Parveen
标识
DOI:10.1080/14656566.2025.2487150
摘要
Taletrectinib shows significant efficacy and favorable safety profile for ROS1-positive NSCLC, particularly in treatment-naïve or tyrosine kinase inhibitor TKI-resistant patients. Further large-scale trials are warranted to confirm its long-term safety and efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI